Huntington’s Patients Can’t Afford FDA Indecision
In 2024, Jeremy Renz’s wife learned she carries the Huntington’s disease gene. Her mother is in the late stages of the disease. The family has watched it move through generations. In January, Renz joined advocates delivering petitions with more than 48,000 signatures to FDA headquarters. His message was simple: “We deserve an answer. We deserve treatment. And the time is now.”
Huntington’s is cruel. Each child of a parent with the gene has a 50 percent chance of inheriting it, and nearly everyone who inherits it will develop the disease, usually between ages 30 and 50. Over the next 10 to 25 years, it will destroy the nerve cells in the brain, taking away control of one’s movements, then their memory, then their life. There is no cure, and nothing on the market slows it down. No wonder as many as 90 percent of the individuals with an affected parent never get tested. Why learn about a death sentence you can’t appeal?
Families like the Renzes may soon get an answer. On November 2, the FDA accepted an application from the Dutch biopharmaceutical company, uniQure, to approve AMT-130, a one-time gene therapy delivered directly into the brain. The agency granted it priority review and set a decision date of May 1, 2027. The company is seeking accelerated approval, which lets treatments for serious diseases reach patients on promising early evidence, as long as the benefit is confirmed later. uniQure has treated 51 patients so far.
Unfortunately, gene therapies face more bureaucratic hurdles than most drugs, leaving little room for anything to be accelerated.
Gene therapies are reviewed by the FDA’s separate biologics center, and every trial site under federal rules must also win sign-off from a local biosafety committee—a process that, until 2019, also ran through an advisory committee in Washington. Each layer brings its own reviews and additional opportunities for someone to say “not yet.”
AMT-130 already has been caught in the FDA’s back-and-forth. Last November, the agency reversed its earlier guidance and said uniQure’s data weren’t strong enough to even apply for approval. Then it strongly recommended a new trial comparing the therapy against sham brain surgery, a fake operation in which some patients would have their skulls drilled but receive no treatment. This June, it reversed course again.
That sham surgery detail matters. Critics note that AMT-130’s headline result—75 percent slower progression after three years—came from comparing treated patients to similar untreated patients in an observational database, not a placebo group. Four-year results were weaker. Fair enough. But for a therapy delivered through brain surgery, the only true placebo is the sham operation, which most experts and advocates consider unethical. The evidence is imperfect because the disease is, not because the drug is suspect.
AMT-130 wouldn’t be the first promising treatment caught in the FDA’s crosshairs. While the agency usually gets there, the key question is how long patients must wait.
Consider sodium dichloroacetate (DCA), a treatment for a rare and often fatal genetic disorder in children (pyruvate dehydrogenase complex deficiency). The FDA rejected it in 2025 and asked for new clinical trials—a tall order for a disease affecting only about 1 in 40,000 births. It took nearly a year and a petition from more than 80 doctors and researchers before the agency relented.
Or omaveloxolone, a treatment for Friedreich’s ataxia, a rare disease that slowly destroys the nervous system. Clinical trials showed it slowed the disease, but the results fell a hair short of the FDA’s preferred statistical threshold. It was eventually approved. Patients needing treatment were required to wait because of a rounding error.
The FDA bears the blame if it approves a drug that disappoints. It bears little blame for the patients who decline or die while it deliberates.
Patients face the opposite math. For a disease with no treatment, uncertain evidence isn’t a reason to wait. It’s a risk many patients would gladly take.
Renz and families such as his have waited long enough.
The FDA should grant accelerated approval, give patients access, skip the advisory committee, and let uniQure move ahead with its planned 200-patient confirmation trial while patients are receiving treatment.
If the follow-up data disappoint, the agency can pull the drug. During COVID-19, an extra advisory panel added weeks to vaccine authorization while some 2,200 Americans died each day. Another meeting won’t produce new data. It will only produce more waiting and suffering.
Raymond J. March is a Research Fellow at the Independent Institute, Oakland, Calif., and Director of FDAReview.org. He is also the Christopher L. Culp Professor of Economics and assistant director of the Free Market Institute at Angelo State University, San Angelo, Texas, and a non-resident fellow with the Challey Institute for Global Innovation and Growth at North Dakota State University.